Long-term proton pump inhibitor use and gastrointestinal cancer

David Y. Graham, Robert M. Genta

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalCurrent Gastroenterology Reports
Volume10
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Gastrointestinal Neoplasms
Proton Pump Inhibitors
Helicobacter pylori
Helicobacter Infections
Stomach
Gastric Parietal Cells
Carcinoid Tumor
Human Development
Polyps
Atrophy
Hyperplasia
Dilatation
Neoplasms
Inflammation
Safety
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Long-term proton pump inhibitor use and gastrointestinal cancer. / Graham, David Y.; Genta, Robert M.

In: Current Gastroenterology Reports, Vol. 10, No. 6, 2008, p. 543-547.

Research output: Contribution to journalArticle

Graham, David Y. ; Genta, Robert M. / Long-term proton pump inhibitor use and gastrointestinal cancer. In: Current Gastroenterology Reports. 2008 ; Vol. 10, No. 6. pp. 543-547.
@article{a095a07ac7e844fb9d905b1cc4781041,
title = "Long-term proton pump inhibitor use and gastrointestinal cancer",
abstract = "Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.",
author = "Graham, {David Y.} and Genta, {Robert M.}",
year = "2008",
doi = "10.1007/s11894-008-0100-1",
language = "English (US)",
volume = "10",
pages = "543--547",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Long-term proton pump inhibitor use and gastrointestinal cancer

AU - Graham, David Y.

AU - Genta, Robert M.

PY - 2008

Y1 - 2008

N2 - Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.

AB - Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=60749113725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749113725&partnerID=8YFLogxK

U2 - 10.1007/s11894-008-0100-1

DO - 10.1007/s11894-008-0100-1

M3 - Article

C2 - 19006608

AN - SCOPUS:60749113725

VL - 10

SP - 543

EP - 547

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 6

ER -